Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Alterity Therapeutics Limited - American Depositary Shares (ATHE)
Company Research
Source: GlobeNewswire
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing Disease Progression – – 12-Month Data from bioMUSE Study Shows Key Biomarker is Associated with Disease Progression in MSA – MELBOURNE, Australia and SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA. Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinic
Show less
Read more
Impact Snapshot
Event Time:
ATHE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHE alerts
High impacting Alterity Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ATHE
News
- Appendix 4C – Q3 FY24 Quarterly Cash Flow Report [Yahoo! Finance]Yahoo! Finance
- Appendix 4C – Q3 FY24 Quarterly Cash Flow ReportGlobeNewswire
- Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia [Yahoo! Finance]Yahoo! Finance
- Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaGlobeNewswire
- Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance